NCT00075829 2021-11-01
BMT CTN 0102
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
Clinical Trials
14 trialsNCT01647165 2019-12-12
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT00033332 2014-04-04
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00389701 2014-01-10
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00017602 2014-01-06
Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00742404 2013-12-18
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00003603 2013-09-20
Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00028886 2013-09-17
Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00416897 2013-08-26
Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003493 2013-07-18
Combination Chemotherapy in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00112879 2013-07-10
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00003007 2013-06-26
Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006232 2013-05-15
Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00438841 2009-03-13
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Unknown